{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:53:17Z","timestamp":1783601597455,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Body-worn sensors (BWS) could provide valuable information in the management of Parkinson\u2019s disease and support therapeutic decisions based on objective monitoring. To study this pivotal step and better understand how relevant information is extracted from BWS results and translated into treatment adaptation, eight neurologists examined eight virtual cases composed of basic patient profiles and their BWS monitoring results. Sixty-four interpretations of monitoring results and the subsequent therapeutic decisions were collected. Relationship between interrater agreements in the BWS reading and the severity of symptoms were analyzed via correlation studies. Logistic regression was used to identify associations between the BWS parameters and suggested treatment modifications. Interrater agreements were high and significantly associated with the BWS scores. Summarized BWS scores reflecting bradykinesia, dyskinesia, and tremor predicted the direction of treatment modifications. Our results suggest that monitoring information is robustly linked to treatment adaptation and pave the way to loop systems able to automatically propose treatment modifications from BWS recordings information.<\/jats:p>","DOI":"10.1038\/s41531-023-00489-x","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:03:32Z","timestamp":1679918612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Symptoms assessment and decision to treat patients with advanced Parkinson\u2019s disease based on wearables data"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3951-4653","authenticated-orcid":false,"given":"Clara","family":"Virbel-Fleischman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavien","family":"Mousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Corvol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Benatru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-1250","authenticated-orcid":false,"given":"David","family":"Bendetowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"B\u00e9reau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie Cochen","family":"De Cock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Drapier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Frismand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Giordana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2417-799X","authenticated-orcid":false,"given":"David","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"R\u00e9tory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grabli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"489_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog, J. E. & Muenter, M. D. Frequency of levodopa\u2010related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 11 (2001).","journal-title":"Mov. Disord."},{"key":"489_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager, R. et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 17, 749\u2013759 (2018).","journal-title":"Lancet Neurol."},{"key":"489_CR3","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez, H. H. et al. Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: Final 12-month, open-label results: Levodopa-Carbidopa Intestinal GEL in PD. Mov. Disord. 30, 500\u2013509 (2015).","journal-title":"Mov. Disord."},{"key":"489_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2008.929","volume":"301","author":"FM Weaver","year":"2009","unstructured":"Weaver, F. M. Bilateral deep brain stimulation vs best medical therapy for patients with advanced parkinson disease: a randomized controlled trial. JAMA 301, 63\u201373 (2009).","journal-title":"JAMA"},{"key":"489_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","volume":"21","author":"P Odin","year":"2015","unstructured":"Odin, P. et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: Consensus from an international survey and discussion program. Parkinsonism Relat. Disord. 21, 1133\u20131144 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"489_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.17925\/ENR.2014.09.01.27","volume":"9","author":"F Bergquist","year":"2014","unstructured":"Bergquist, F. & Horne, M. Can objective measurements improve treatment outcomes in Parkinson\u2019s disease? Eur. Neurol. Rev. 9, 27 (2014).","journal-title":"Eur. Neurol. Rev."},{"key":"489_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-018-0046-4","volume":"4","author":"P Farzanehfar","year":"2018","unstructured":"Farzanehfar, P. et al. Objective measurement in routine care of people with Parkinson\u2019s disease improves outcomes. NPJ Parkinsons Dis. 4, 10 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"489_CR8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/14737175.2018.1503948","volume":"18","author":"R Pahwa","year":"2018","unstructured":"Pahwa, R. et al. Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson\u2019s disease: recommendations from an expert panel. Expert Rev. Neurother. 18, 669\u2013680 (2018).","journal-title":"Expert Rev. Neurother."},{"key":"489_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cns.12807","volume":"24","author":"D Johansson","year":"2018","unstructured":"Johansson, D. et al. Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry. CNS Neurosci. Ther. 24, 439\u2013447 (2018).","journal-title":"CNS Neurosci. Ther."},{"key":"489_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JPD-2012-11071","volume":"2","author":"RI Griffiths","year":"2012","unstructured":"Griffiths, R. I. et al. Automated assessment of bradykinesia and dyskinesia in Parkinson\u2019s disease. J. Parkinsons Dis. 2, 47\u201355 (2012).","journal-title":"J. Parkinsons Dis."},{"key":"489_CR11","doi-asserted-by":"publisher","first-page":"e0124522","DOI":"10.1371\/journal.pone.0124522","volume":"10","author":"MK Horne","year":"2015","unstructured":"Horne, M. K., McGregor, S. & Bergquist, F. An objective fluctuation score for Parkinson\u2019s disease. PLoS ONE 10, e0124522 (2015).","journal-title":"PLoS ONE"},{"key":"489_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JPD-160898","volume":"6","author":"M Braybrook","year":"2016","unstructured":"Braybrook, M. et al. An ambulatory tremor score for Parkinson\u2019s disease. J. Parkinsons Dis. 6, 723\u2013731 (2016).","journal-title":"J. Parkinsons Dis."},{"key":"489_CR13","doi-asserted-by":"publisher","first-page":"e0161559","DOI":"10.1371\/journal.pone.0161559","volume":"11","author":"C Ossig","year":"2016","unstructured":"Ossig, C. et al. Correlation of quantitative motor state assessment using a kinetograph and patient diaries in advanced PD: data from an observational study. PLoS ONE 11, e0161559 (2016).","journal-title":"PLoS ONE"},{"key":"489_CR14","first-page":"15","volume":"2","author":"M Horne","year":"2016","unstructured":"Horne, M., Kotschet, K. & McGregor, S. The clinical validation of objective measurement of movement in Parkinson\u2019s disease. Cent. Nerv. Syst. 2, 15\u201322 (2016).","journal-title":"Cent. Nerv. Syst"},{"key":"489_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3233\/JPD-181373","volume":"9","author":"A Santiago","year":"2019","unstructured":"Santiago, A. et al. Qualitative evaluation of the personal KinetiGraphTM movement recording system in a Parkinson\u2019s clinic. J. Parkinsons Dis. 9, 207\u2013219 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"489_CR16","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.3390\/s19235153","volume":"19","author":"H Khodakarami","year":"2019","unstructured":"Khodakarami, H. et al. Prediction of the levodopa challenge test in Parkinson\u2019s disease using data from a wrist-worn sensor. Sensors 19, 5153 (2019).","journal-title":"Sensors"},{"key":"489_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4236\/apd.2019.83005","volume":"08","author":"FB Nahab","year":"2019","unstructured":"Nahab, F. B., Abu-Hussain, H. & Moreno, L. Evaluation of clinical utility of the personal KinetiGraph\u00ae in the management of Parkinson disease. Adv. Parkinsons Dis. 08, 42\u201361 (2019).","journal-title":"Adv. Parkinsons Dis."},{"key":"489_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41531-018-0051-7","volume":"4","author":"P Odin","year":"2018","unstructured":"Odin, P. et al. Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson\u2019s disease. NPJ Parkinsons Dis. 4, 14 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"489_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gaitpost.2017.09.031","volume":"59","author":"\u00c0 Bay\u00e9s","year":"2018","unstructured":"Bay\u00e9s, \u00c0. et al. A \u201cHOLTER\u201d for Parkinson\u2019s disease: validation of the ability to detect on-off states using the REMPARK system. Gait Posture 59, 1\u20136 (2018).","journal-title":"Gait Posture"},{"key":"489_CR20","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/mds.26642","volume":"31","author":"AJ Espay","year":"2016","unstructured":"Espay, A. J. et al. Technology in Parkinson\u2019s disease: challenges and opportunities. Mov. Disord. 31, 1272\u20131282 (2016).","journal-title":"Mov. Disord."},{"key":"489_CR21","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3390\/s19102241","volume":"19","author":"H Khodakarami","year":"2019","unstructured":"Khodakarami, H., Farzanehfar, P. & Horne, M. The use of data from the Parkinson\u2019s KinetiGraph to identify potential candidates for device assisted therapies. Sensors 19, 2241 (2019).","journal-title":"Sensors"},{"key":"489_CR22","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.parkreldis.2015.04.030","volume":"21","author":"A Rodr\u00edguez-Molinero","year":"2015","unstructured":"Rodr\u00edguez-Molinero, A. et al. Remote control of apomorphine infusion rate in Parkinson\u2019s disease: Real-time dose variations according to the patients\u2019 motor state. A proof of concept. Parkinsonism Relat. Disord. 21, 996\u2013998 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"489_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41531-019-0094-4","volume":"5","author":"DJ van Wamelen","year":"2019","unstructured":"van Wamelen, D. J. et al. Non-motor correlates of wrist-worn wearable sensor use in Parkinson\u2019s disease: an exploratory analysis. NPJ Parkinsons Dis. 5, 22 (2019).","journal-title":"NPJ Parkinsons Dis."},{"key":"489_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-017-0038-9","volume":"4","author":"S McGregor","year":"2018","unstructured":"McGregor, S. et al. The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson\u2019s disease. NPJ Parkinsons Dis. 4, 1 (2018).","journal-title":"NPJ Parkinsons Dis."},{"key":"489_CR25","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/ene.13015","volume":"23","author":"L Klingelhoefer","year":"2016","unstructured":"Klingelhoefer, L. et al. Night-time sleep in Parkinson\u2019s disease - the potential use of Parkinson\u2019s KinetiGraph: a prospective comparative study. Eur. J. Neurol. 23, 1275\u20131288 (2016).","journal-title":"Eur. J. Neurol."},{"key":"489_CR26","doi-asserted-by":"publisher","unstructured":"Sam\u00e0, P.-L. et al. A double closed loop to enhance the quality of life of Parkinson\u2019s Disease patients: REMPARK system. Stud. Health Technol. Inform. 115\u2013124. https:\/\/doi.org\/10.3233\/978-1-61499-474-9-115 (2014).","DOI":"10.3233\/978-1-61499-474-9-115"},{"key":"489_CR27","doi-asserted-by":"crossref","unstructured":"Cancela, J. et al. Monitoring of motor and non-motor symptoms of Parkinson\u2019s disease through a mHealth platform. In Proc 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 663\u2013666 (IEEE, 2016).","DOI":"10.1109\/EMBC.2016.7590789"},{"key":"489_CR28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/sim.2294","volume":"25","author":"Y Saito","year":"2006","unstructured":"Saito, Y., Sozu, T., Hamada, C. & Yoshimura, I. Effective number of subjects and number of raters for inter-rater reliability studies. Stat. Med. 25, 1547\u20131560 (2006).","journal-title":"Stat. Med."},{"key":"489_CR29","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"489_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","volume":"82","author":"F Ory-Magne","year":"2014","unstructured":"Ory-Magne, F. et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology 82, 300\u2013307 (2014).","journal-title":"Neurology"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00489-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00489-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00489-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T12:10:10Z","timestamp":1679919010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00489-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00489-x","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"21 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing non-financial interests but the following competing financial interests: C.V.F. received a grant from Association Nationale de la Recherche et de la Technologie (A.N.R.T.) and full-time employment by Air Liquide Healthcare. F.M., Y.R., S.L. and S.H. declared full-time employment by Air Liquide Healthcare at the time of the study. J.C.C. served on advisory boards for Air Liquide, Biogen, BrainEver, Denali, EverPharma, Prevail Therapeutic, UCB, and received grants from Sanofi outside of this work. I.B. served on scientific advisory boards for AbbVie and Orkyn. D.B. received travel grants from Boston Scientific and research support grant from Fondation Recherche M\u00e9dicale. M.B. reports reimbursement of travel expenses to scientific meetings from ELIVIE, Medtronic and Boston Scientific, honoraria from Merz Pharma and Allergan for lecturing, outside the submitted work. V.C.D.C. and S.F. declare no conflict of interest. S.D. declares boards and congress with Medtronic, Orkyn, AbbVie, LVL, Homeperf, Elivie. C.G. received grants from Abbot and Abbvie. D.D. served on several Scientific Advisory Boards for Orkyn, Air Liquide, Lundbeck, Ever Pharma and Boston Scientific, he has equity stake in InBrain Pharma. D.G. received grants from AP-HP (DRC-PHRC) and France Parkinson, served on scientific advisory boards for AbbVie and Zambon; received research funding from Air Liquide; received speech honorarium from Medtronic, Abbvie and Merz; received travel funding from Abbvie and Merz.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}